CSL Shares Gain on Lilly Partnership and Buyback Momentum
CSL Limited (CSL.AX) ROSE 0.95% to A$154.19, extending gains for a second session as investors responded to strategic moves. The biopharma firm secured a US$100 million upfront payment from Eli Lilly for clazakizumab rights, retaining cardiovascular application exclusivity. Its ongoing share repurchase program further buoyed sentiment.
Market-wide risk appetite lifted the S&P/ASX 200 by 0.9%, though CSL remains 15% below February peaks. The deal structure—milestone payments plus royalties—offers long-term revenue optionality while buybacks provide technical support. An April interim dividend maintains capital return focus amid earnings season volatility.